Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
Laryngomalacia, Gastro Esophageal Reflux
About this trial
This is an interventional treatment trial for Laryngomalacia focused on measuring Laryngomalacia, Symptom improvement, Famotidine, Speech Language Therapy
Eligibility Criteria
Inclusion Criteria:
- Pediatric patients ages 0 to 6 months who do need meet the criteria at the initial appointment for supraglottoplasty
- Seen in University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh (CHP) Otolaryngology Department
- Laryngomalacia without prolonged (>20 seconds) cyanosis, apnea, nor failure to thrive.
Exclusion Criteria:
- Children over the age of 6 months old will be excluded from participation.
- Premature infants (<37 weeks gestation)
- Patients with lung disease.
- Laryngomalacia with prolonged (>20 seconds) cyanosis, apnea, and failure to thrive
- Sleep induced laryngomalacia
- Patients with craniofacial abnormalities
- Patients with a syndrome
- Patients with additional airway abnormalities, seen before or at consult
- Patients with symptoms that necessitate surgery
- Patients with a prior cardiac surgery
- Patients with AST prescribed prior to the initial otolaryngology consult.
Sites / Locations
- UPMC Children's Hospital of PittsburghRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Speech Language Therapy Alone
Speech Language Therapy and Acid Suppression Therapy
Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.